Skip to Main content Skip to Navigation
Journal articles

FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence biological activities beyond hemostasis: Factor VIIIbeyond hemostasis

Abstract : Hemophilia A is an X-linked hereditary disorder related to the deficiency of coagulation factor VIII (FVIII) leading to spontaneous bleeding episodes particularly into joints and muscles. FVIII deficiency has been associated with altered bone remodeling, dysregulated macrophage polarization, and inflammatory processes combined with neoformation of abnormal blood vessels. Treatment based on FVIII can lead to the development of inhibitors that render FVIII concentrate infusion ineffective. In this context, hemophilia has entered a new therapeutic era with the development of new drugs (e.g. Emicizumab) to restore the hemostatic balance by bypassing pathologic acquired antibodies. The present review aims to discuss the potential extrahemostatic functions of FVIII which may be crucial information for defining the future therapies in hemophilia.
Complete list of metadata

https://www.hal.inserm.fr/inserm-03298299
Contributor : Dominique Heymann Connect in order to contact the contributor
Submitted on : Friday, July 23, 2021 - 3:12:59 PM
Last modification on : Wednesday, October 20, 2021 - 3:19:38 AM
Long-term archiving on: : Sunday, October 24, 2021 - 6:46:11 PM

Files

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-01-23

Please log in to resquest access to the document

Identifiers

Collections

`

Citation

Marie Cadé, Javier Munoz-Garcia, Antoine Babuty, M. Marc Fouassier, Marie-Françoise Heymann, et al.. FVIII at the crossroad of coagulation, bone and immune biology: emerging evidence biological activities beyond hemostasis: Factor VIIIbeyond hemostasis. Drug Discovery Today, Elsevier, 2021, pp.S1359-6446(21)00321-4. ⟨10.1016/j.drudis.2021.07.015⟩. ⟨inserm-03298299⟩

Share

Metrics

Record views

21